KMDA
Kamada Ltd.
$7.85
+3.15% 2026-10-20
Healthcare
KMDASPY
1W
+2.1%
1M
-11.3%
3M
+10.1%
6M
-1.3%
YTD
+16.9%
1Y
+16.6%
Live chart
Loading live chart…
Grades vs sector
MomentumNot enough data yet–
Momentum
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Growth
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Value
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Profitability
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsKamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026
GlobeNewswire · Oct 19
Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel
MT Newswires · Oct 06
Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel
GlobeNewswire · Oct 06
Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth
MarketBeat · Sep 27
Kamada Maintains 'Sufficient' KedRAB Supply, Production Capacity Amid Increasing Rabies Exposures in US
MT Newswires · Sep 17
Key stats
Market cap$453.0M
P/E (trailing)20.7
P/E (forward)13.6
52-week range6.55 – 9.35
Revenue growth (YoY, latest qtr)+22.7%
Dividend yield2.23%
Analyst consensusStrong Buy (4)
Mean price target$13.50 (+72%)
Valuation and fundamentals
Valuation & fundamentals
No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).
Earnings
Next report: 2026-11-09 · before open · EPS est 0.13
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | 0.11 | 0.16 | +42.2% |
| 2026-05-13 | 0.12 | 0.07 | -39.1% |
| 2026-03-11 | 0.08 | 0.06 | -22.6% |
| 2025-11-10 | 0.09 | 0.09 | -2.7% |
| 2025-08-13 | 0.09 | 0.13 | +44.4% |
| 2025-05-14 | 0.07 | 0.07 | +3.7% |
| 2025-03-05 | 0.05 | 0.07 | +31.3% |
| 2024-11-13 | 0.07 | 0.07 | – |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $54.9M | +22.7% |
| 2026-03-31 | $45.2M | – |
| 2025-12-31 | $44.7M | – |
| 2025-09-30 | $47.0M | – |
| 2025-06-30 | $44.8M | – |
Analyst actions
HC Wainwright & Co.
PT $13
2025-12-09 · main
Buy → BuyPT $13
Benchmark
PT $15
2025-05-15 · reit
Buy → BuyPT $15
Benchmark
PT $15
2025-03-21 · init
→ BuyPT $15
HC Wainwright & Co.
PT $11
2025-03-06 · reit
Buy → BuyPT $11
HC Wainwright & Co.
PT $11
2025-01-10 · reit
Buy → BuyPT $11
HC Wainwright & Co.
PT $11
2024-11-14 · reit
Buy → BuyPT $11
Recent dividends
2026-08-27: $0.170 · 2026-03-23: $0.250 · 2025-03-17: $0.200 · 2013-06-13: $0.006
Insider trades
Tsur David
$186.7K
Director · 2026-09-14
SELL$186.7K
Tsur David
$1.4K
Director · 2026-09-09
SELL$1.4K
Tsur David
$1.3M
Director · 2026-09-08
SELL$1.3M
Tsur David
$117.9K
Director · 2026-09-07
SELL$117.9K
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
Stats refreshed 2026-10-20 18:14:17 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.